Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Risk-Stratified Real-World Multicenter Study of the Efficacy and Safety of CD20 Monoclonal Antibody-Based First-Line Therapy in Treatment-Naive Marginal Zone B-Cell Lymphoma

NCT07492407 is registered in ClinicalTrials.gov with Henan Cancer Hospital as lead sponsor.

NCT NCT07492407
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07492407 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Risk-Stratified Real-World Multicenter Study of the Efficacy and Safety of CD20 Monoclonal Antibody-Based First-Line Therapy in Treatment-Naive Marginal Zone B-Cell Lymphoma
Lead sponsor
Henan Cancer Hospital
Phase
Observational
Overall status
Not yet recruiting
Start date
April 30, 2026
Completion date
February 29, 2028
Enrollment
131 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

mzl